v3.25.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 75,060 $ 101,654
Short-term restricted cash 80 1,330
Investment in equity securities 8,801 3,529
Trade and other receivables, net 1,817 1,839
Short-term royalty and commercial payment receivables under the EIR method 17,960 14,763
Short-term royalty and commercial payment receivables under the cost recovery method 700 413
Prepaid expenses and other current assets 507 2,076
Total current assets 104,925 125,604
Long-term restricted cash 3,345 3,432
Property and equipment, net 26 32
Operating lease right-of-use assets 288 319
Long-term royalty and commercial payment receivables under the EIR method 4,775 4,970
Long-term royalty and commercial payment receivables under the cost recovery method 58,937 55,936
Exarafenib milestone asset 3,402 3,214
Investment in warrants 609  
Intangible assets, net 45,434 25,909
Other assets - long term 1,715 1,861
Total assets 223,456 221,277
Current liabilities:    
Accounts payable 1,138 1,053
Accrued and other liabilities 5,411 5,752
Contingent consideration under RPAs, AAAs, and CPPAs   3,000
Operating lease liabilities 472 446
Unearned revenue recognized under units-of-revenue method 1,434 1,361
Preferred stock dividend accrual 1,368 1,368
Current portion of long-term debt 11,672 11,394
Total current liabilities 21,495 24,374
Unearned revenue recognized under units-of-revenue method - long-term 3,666 4,410
Exarafenib milestone contingent consideration (Note 4) 3,402 3,214
Long-term operating lease liabilities 238 483
Long-term debt 102,201 106,875
Total liabilities 131,002 139,356
Commitments and Contingencies (Note 10)
Convertible preferred stock, $0.05 par value, 5,003 shares authorized, issued and outstanding as of June 30, 2025 and December 31, 2024 20,019 20,019
Stockholders' equity:    
Common stock, $0.0075 par value, 277,333,332 shares authorized, 12,062,466 and 11,952,377 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 90 90
Additional paid-in capital 1,300,066 1,298,747
Accumulated other comprehensive income 122 73
Accumulated deficit (1,227,892) (1,237,057)
Total stockholders' equity 72,435 61,902
Total liabilities and stockholders' equity 223,456 221,277
8.625% Series A Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock 49 49
8.375% Series B Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock